{"id":50998,"date":"2022-11-17T16:02:29","date_gmt":"2022-11-17T15:02:29","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/understanding-the-link-between-nafld-and-diabetes-echosens-points-to-new-aace-guideline-supporting-fibroscan-as-key-component-of-type-2-diabetes-management\/"},"modified":"2022-11-17T16:02:29","modified_gmt":"2022-11-17T15:02:29","slug":"understanding-the-link-between-nafld-and-diabetes-echosens-points-to-new-aace-guideline-supporting-fibroscan-as-key-component-of-type-2-diabetes-management","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/understanding-the-link-between-nafld-and-diabetes-echosens-points-to-new-aace-guideline-supporting-fibroscan-as-key-component-of-type-2-diabetes-management\/","title":{"rendered":"Understanding the Link Between NAFLD and Diabetes: Echosens Points to New AACE Guideline Supporting FibroScan as Key Component of Type 2 Diabetes Management"},"content":{"rendered":"
\n

\nEchosens Recognizes November 2022 American Diabetes Month, Urges Non-invasive Detection, Monitoring of Liver Fat and Stiffness<\/i>\n<\/p>\n

WALTHAM, Mass.–(BUSINESS WIRE)–#FibroScan<\/a>—Echosens North America<\/a>, a high-technology company offering the FibroScan\u00ae<\/sup> portfolio of solutions, recognizes the importance of American Diabetes Month<\/a> this November for bringing greater attention to the value of non-invasive technology, such as FibroScan<\/a>, to measure and monitor liver stiffness and detect nonalcoholic fatty liver disease (NAFLD). According to the American Association of Clinical Endocrinology<\/a> (AACE), the risk of NAFLD, a common co-morbidity of Type 2 diabetes, is two-to-threefold higher in individuals with Type 2 diabetes mellitus and\/or obesity but can be halted or reversed if detected in its earliest stages.\n<\/p>\n

<\/a><\/p>\n

\nThese new guideline recommendations as reported in AACE reinforce the use of FibroScan solutions for the management of patients with NAFLD throughout the patient care continuum. The recommendations are a breakthrough in early diagnosis and management of patients with NAFLD, targeting primary care and endocrinology clinical settings.\n<\/p>\n

\n\u201cAmerican Diabetes Month is an ideal opportunity to highlight this new guideline which includes 34 evidence-based clinical practice recommendations for the screening, diagnosis, and management of adults and children with NAFLD and\/or NASH,\u201d says Jon Gingrich, CEO, Echosens, North America. \u201cLeft undiagnosed, these conditions can be difficult to control, making early interventions more important than ever in helping individuals introduce lifestyle changes that can slow disease progression.\u201d\n<\/p>\n

\nAACE recommendations related to FibroScan include:\n<\/p>\n